Steadybase.

Hemab Therapeutics Holdings, Inc.

Website Investor relations LinkedIn
  • COAG ยท Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Cambridge, MA
  • CIK 0002114044

Updated from SEC filings through

Top things to know

Executives

Hemab Therapeutics Holdings, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Cambridge, MA. It trades as COAG on Nasdaq.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Catherine Madigan Chief Medical Officer Form 4, May 4, 2026
Ananthram Sreenivasa Murthy Chief Operating Officer Form 3, April 30, 2026

What Hemab Therapeutics Holdings, Inc. does

Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 46.7 million (as of October 30, 2026) 10-Q, November 10, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 10, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
May 6, 2026 Peter Kolchinsky
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026
May 6, 2026 Rajeev M. Shah
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026
May 6, 2026 Capital Nexus Fund L.P. RA II
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026
May 6, 2026 Capital Nexus Fund L.P. RA IV
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026
May 6, 2026 Capital Healthcare Fund LP RA
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026
May 6, 2026 Capital Management L.P. Ra
Director
Buy 2,840,429 $52.2M Form 4, May 6, 2026

Recent 8-K events

Frequently asked questions about Hemab Therapeutics Holdings, Inc.

What does Hemab Therapeutics Holdings, Inc. do?
In its own words, from Item 1 of its 10-K: "Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders."
Where is Hemab Therapeutics Holdings, Inc. headquartered?
Cambridge, MA.
What is Hemab Therapeutics Holdings, Inc.'s stock ticker?
COAG on Nasdaq.
What industry is Hemab Therapeutics Holdings, Inc. in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Hemab Therapeutics Holdings, Inc.'s website?
hemab.com. Investor relations: https://ir.hemab.com/.
When does Hemab Therapeutics Holdings, Inc. report earnings next?
January 31, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Hemab Therapeutics Holdings, Inc. a public company?
Yes. Hemab Therapeutics Holdings, Inc. files with the SEC under CIK 0002114044 and trades as COAG.
How many shares of Hemab Therapeutics Holdings, Inc. are outstanding?
46.7 million shares as of October 30, 2026, from its 10-Q filed November 10, 2026.
How many business segments does Hemab Therapeutics Holdings, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 10, 2026.
Have Hemab Therapeutics Holdings, Inc. insiders traded stock recently?
Since May 6, 2026, officers and directors reported 0 open-market sales and 6 purchases worth about $313M on Forms 4 and 5. The most recent: Peter Kolchinsky (Director) bought 2,840,429 shares on May 6, 2026.